EUVIMEDEUVIMED entdecken
Crossref

Discovery of DT-9081, a Potent and Orally Bioavailable Small Molecule Antagonist of the EP4 Receptor for the Treatment of Solid Cancers

Anne-Laure Blayo, Gaël Hommet, Mickaël Fer, Célia Halter, Camille Amalric, Philippe Cluzeau, Gaële Fraboulet, Sitty Mikidadi, Noémie Lotz, Sébastien Tarlet, Ludovic Herbin, Baptiste Manteau und 12 weitere

Journal of Medicinal Chemistry · 24.09.2026 · 69 (18) · 21139-21163

DOI: 10.1021/acs.jmedchem.6c00863 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, online erschienen am 08.09.2026. Verfasst von Anne-Laure Blayo und 23 weiteren Autor:innen. Beteiligte Einrichtung: Kainova Therapeutics, 220 Boulevard Gonthier d'Andernach, 67400Illkirch - Strasbourg, France. Hauptthemen laut MEDLINE: Receptors, Prostaglandin E, EP4 Subtype, Antineoplastic Agents, Drug Discovery, Neoplasms. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 24 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The EP4 receptor (EP4R) has emerged as a promising target in immuno-oncology due to its role in modulating tumor immunity and inflammation. Here, we describe the discovery and preclinical development of DT-9081, a clinical candidate EP4R-antagonist that has completed a phase I monotherapy trial for the treatment of solid cancers. A scaffold hopping strategy enabled the identification of a novel chemical series with improved activity and pharmacokinetics. Structure−activity relationship (SAR) studies guided the optimization of lead compounds, culminating in the identification of DT-9081, which exhibits potent EP4R antagonism, favorable ADME characteristics, and an excellent preclinical safety profile. Comprehensive in vitro and in vivo pharmacology data further support the utility of DT-9081 in modulating tumor immunity, providing a compelling rationale for its clinical development in the treatment of solid cancers.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Receptors, Prostaglandin E, EP4 SubtypeAntineoplastic AgentsDrug DiscoveryNeoplasmsHumansAnimalsStructure-Activity RelationshipAdministration, OralBiological AvailabilityMiceRatsCell Line, TumorFemale

Substanzen

Receptors, Prostaglandin E, EP4 SubtypeAntineoplastic Agents

Autor:innen und Institutionen

  • Kainova Therapeutics, 220 Boulevard Gonthier d'Andernach, 67400Illkirch - Strasbourg, France.

ORCID-Profile: Stephan Schann

Zitieren

APA

Blayo, A. L., Hommet, G., Fer, M., Halter, C., Amalric, C., Cluzeau, P., Fraboulet, G., Mikidadi, S., Lotz, N., Tarlet, S., Herbin, L., Manteau, B., Schappler, M., Deshons, L., Dumont, A., Baron, L., Steinberg, E., Dietsch, C., Lecru, L., …, & Schann, S. (2026). Discovery of DT-9081, a Potent and Orally Bioavailable Small Molecule Antagonist of the EP4 Receptor for the Treatment of Solid Cancers. Journal of Medicinal Chemistry, 69(18), 21139-21163. https://doi.org/10.1021/acs.jmedchem.6c00863

Vancouver

Blayo AL, Hommet G, Fer M, Halter C, Amalric C, Cluzeau P, et al. Discovery of DT-9081, a Potent and Orally Bioavailable Small Molecule Antagonist of the EP4 Receptor for the Treatment of Solid Cancers. Journal of Medicinal Chemistry. 2026;69(18):21139-21163. doi:10.1021/acs.jmedchem.6c00863

BibTeX
@article{Blayo2026,
  author = {Blayo, Anne-Laure and Hommet, Gaël and Fer, Mickaël and Halter, Célia and Amalric, Camille and Cluzeau, Philippe and Fraboulet, Gaële and Mikidadi, Sitty and Lotz, Noémie and Tarlet, Sébastien and Herbin, Ludovic and Manteau, Baptiste and Schappler, Malaury and Deshons, Laurène and Dumont, Alexia and Baron, Luc and Steinberg, Edith and Dietsch, Camille and Lecru, Lola and Maurin, Thomas and Franchet, Christel and Dorange, Ismet and Mayer, Stanislas and Schann, Stephan},
  title = {Discovery of DT-9081, a Potent and Orally Bioavailable Small Molecule Antagonist of the EP4 Receptor for the Treatment of Solid Cancers},
  journal = {Journal of Medicinal Chemistry},
  year = {2026},
  volume = {69},
  number = {18},
  pages = {21139--21163},
  doi = {10.1021/acs.jmedchem.6c00863}
}
Kostenlos starten →